An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK

British Journal of Pharmacology

Volumn 168, Issue 7, 2013, Pages 1647-1661

  Kim, Tae Hyun ^a   Eom, Jeong Sik ^a   Lee, Chan Gyu ^a   Yang, Yoon Mee ^a   Lee, Yong Sup ^b   Kim, Sang Geon ^a  

^a Seoul National University   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

AMP; AMPK; high fat diet; LKB1; LXR ; steatohepatitis

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER KINASE B1; MITOCHONDRIAL DNA; OLTIPRAZ; PROTEIN KINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; FATTY LIVER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID DIET; LIPOGENESIS; LIVER MITOCHONDRION; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; OXIDATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT RESPONSE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; DIET, HIGH-FAT; ENZYME ACTIVATION; FATTY LIVER; HEP G2 CELLS; HUMANS; LIPID METABOLISM; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; ORPHAN NUCLEAR RECEPTORS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PYRAZINES; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84875156150     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12057     Document Type: Article

References (43)

1. Aharoni-Simon M, Hann-Obercyger M, Pen S, Madar Z, Tirosh O, (2011). Fatty liver is associated with impaired activity of PPARγ-coactivator 1α (PGC-1α) and mitochondrial biogenesis in mice. Lab Invest 91: 1018-1028.
2. Aquilano K, Vigilanza P, Baldelli S, Pagliei B, Rotilio G, Ciriolo MR, (2010). Peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-1alpha) and sirtuin 1 (SIRT1) reside in mitochondria: possible direct function in mitochondrial biogenesis. J Biol Chem 285: 21590-21599.
3. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, et al,. (2005). Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 1: 259-271.
4. Bae EJ, Yang YM, Kim JW, Kim SG, (2007). Identification of a novel class of dithiolethiones that prevent hepatic insulin resistance via the adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway. Hepatology 46: 730-739.
5. Bae SK, Kim EJ, Chung SJ, Kim SG, Lee MG, (2003). Pharmacokinetic interaction between oltipraz and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) after single intravenous and oral administration to rats. J Pharm Pharmacol 55: 1241-1249.
6. Berk PD, (2008). Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology 48: 1362-1376.
7. Bolton MG, Muñoz A, Jacobson LP, Groopman JD, Maxuitenko YY, Roebuck BD, et al,. (1993). Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. Cancer Res 53: 3499-3504.
8. Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J, (2004). Carnitine palmitoyl transferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 25: 495-520.
9. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al,. (2005). A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100: 1082-1090.
10. Crunkhorn S, Dearie F, Mantzoros C, Gami H, da Silva WS, Espinoza D, et al,. (2007). Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation. J Biol Chem 282: 15439-15450.
11. Day CP, James OF, (1998). Steatohepatitis: a tale of two 'hits'? Gastroenterology 114: 842-845.
12. Fabbrini E, Sullivan S, Klein S, (2010). Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51: 679-689.
13. Frezza C, Cipolat S, Scorrano L, (2007). Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat Protoc 2: 287-295.
14. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N, (2005). Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280: 32081-32089.
15. Han CY, Ki SH, Kim YW, Noh K, Lee Y, Kang B, et al,. (2011). Ajoene, a stable garlic by-product, inhibits high-fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activation. Antioxid Redox Signal 14: 187-202.
16. Hancock CR, Han DH, Chen M, Terada S, Yasuda T, Wright DC, et al,. (2008). High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Proc Natl Acad Sci U S A 105: 7815-7820.
17. Hwahng SH, Ki SH, Bae EJ, Kim HE, Kim SG, (2009). Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 49: 1913-1925.
18. Kang KW, Kim YG, Cho MK, Bae SK, Kim CW, Lee MG, et al,. (2002). Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 16: 1988-1990.
19. Kang KW, Cho IJ, Lee CH, Kim SG, (2003). Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S-transferase by oltipraz. J Natl Cancer Inst 95: 53-66.
20. Kang SG, Lee WH, Lee YH, Lee YS, Kim SG, (2012). Hypoxia-inducible factor-1α inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction. Carcinogenesis 33: 661-669.
21. Karaskov E, Scott C, Zhang L, Teodoro T, Ravazzola M, Volchuk A, (2006). Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis. Endocrinology 147: 3398-3407.
22. Kerner J, Hoppel C, (2000). Fatty acid import into mitochondria. Biochim Biophys Acta 1486: 1-17.
23. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W, (1999). Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103: 1489-1498.
24. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
25. Kim SG, Kim YM, Choi YH, Lee MG, Choi JY, Han JY, et al,. (2010). Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1. Clin Pharmacol Ther 88: 360-368.
26. Ko MS, Lee SJ, Kim JW, Lim JW, Kim SG, (2006). Differential effects of the oxidized metabolites of oltipraz on the activation of CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 for GSTA2 gene induction. Drug Metab Dispos 34: 1353-1360.
27. Kwon YN, Shin SM, Cho IJ, Kim SG, (2009). Oxidized metabolites of oltipraz exert cytoprotective effects against arachidonic acid through AMP-activated protein kinase-dependent cellular antioxidant effect and mitochondrial protection. Drug Metab Dispos 37: 1187-1197.
28. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, et al,. (2001). Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol 21: 7558-7568.
29. Lage R, Dieguez C, Vidal-Puig A, Lopez M, (2008). AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 14: 539-549.
30. Lee Y, Wang MY, Kakuma T, Wang ZW, Babcock E, McCorkle K, et al,. (2001). Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem 276: 5629-5635.
31. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
32. Mahady SE, Webster AC, Walker S, Sanyal A, George J, (2011). The role of thiazolidinediones in non-alcoholic steatohepatitis-a systematic review and meta analysis. J Hepatol 55: 1383-1390.
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
34. Orellana-Gavaldà JM, Herrero L, Malandrino MI, Pañeda A, Sol Rodríguez-Peña M, Petry H, et al,. (2012). Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation. Hepatology 53: 821-832.
35. Patsouris D, Reddy JK, Müller M, Kersten S, (2006). Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147: 1508-1516.
36. Pyper SR, Viswakarma N, Yu S, Reddy JK, (2010). PPARα: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal 8: e002.
37. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, et al,. (2011). A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 54: 1011-1019.
38. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al,. (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101: 3329-3335.
39. Shin SM, Kim SG, (2009). Inhibition of arachidonic acid and iron-induced mitochondrial dysfunction and apoptosis by oltipraz and novel 1,2-dithiole-3-thione congeners. Mol Pharmacol 75: 242-253.
40. Velayutham M, Muthukumaran RB, Sostaric JZ, McCraken J, Fishbein JC, Zweier JL, (2007). Interactions of the major metabolite of the cancer chemopreventive drug oltipraz with cytochrome c: a novel pathway for cancer chemoprevention. Free Radic Biol Med 43: 1076-1085.
41. Yoon MC, (2009). The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res Rev 60: 151-159.
42. Zelcer N, Tontonoz P, (2005). Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116: 607-614.
43. Zhang BB, Zhou G, Li C, (2009). AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9: 407-416.